Comparative Pharmacology

Head-to-head clinical analysis: DEXLANSOPRAZOLE versus ZEGERID OTC.

Peer-Reviewed Evidence

Differential Analysis

DEXLANSOPRAZOLE vs ZEGERID OTC

Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.

DEXLANSOPRAZOLE

Proton Pump Inhibitor

Category A/B

ZEGERID OTC

Proton Pump Inhibitor

Category C

Head-to-Head

Clinical Matrix

Mechanism of Action

Proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the (H+, K+)-ATPase enzyme system at the secretory surface of the gastric parietal cell.

Omeprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by irreversibly binding to the H+/K+-ATPase enzyme (the proton pump) in the gastric parietal cells.

Clinical Dosing

30 mg orally once daily for 4 weeks for healing of erosive esophagitis; maintenance therapy: 30 mg orally once daily for up to 6 months. For GERD: 30 mg orally once daily for 4 weeks.

20 mg orally once daily before a meal for 14 days for frequent heartburn; 20 mg orally once daily for up to 8 weeks for erosive esophagitis healing; 20 mg orally once daily for maintenance of healed erosive esophagitis (up to 12 months).

Direct Interaction

None Documented

Half-Life

Other Significant Interactions

Clinical Note

moderate

Dexlansoprazole + Clodronic acid

"The therapeutic efficacy of Clodronic acid can be decreased when used in combination with Dexlansoprazole."

Clinical Note

moderate

Dexlansoprazole + Alendronic acid

"The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Dexlansoprazole."

Clinical Note

moderate

Dexlansoprazole + Technetium Tc-99m medronate

"The therapeutic efficacy of Technetium Tc-99m medronate can be decreased when used in combination with Dexlansoprazole."

Clinical Note

moderate